1xbet 카지노 Pharmaceutical Co., Ltd.
Pharmaceuticals
May 8, 2012
The Federal Circuit Decision Affirming the Validity of the Asserted Claims of 1xbet 카지노's Patent to ABILIFY®
Tokyo, Japan, May 8, 2012 - 1xbet 카지노 Pharmaceutical Co., Ltd. and 1xbet 카지노 Holdings, Co., Ltd., the parent company of 1xbet 카지노 Pharmaceutical Co., Ltd., announced today that the U.S. Court of Appeals for the Federal Circuit issued its judgment dated May 7, 2012 in favor of 1xbet 카지노 Pharmaceutical Co., Ltd. in its patent litigation against several companies seeking FDA approval to market generic copies of ABILIFY®
1xbet 카지노 Federal Circuit affirmed 1xbet 카지노 only issue on appeal from 1xbet 카지노 district court's decision, holding that 1xbet 카지노 asserted claims of U.S. Patent No. 5,006,528 covering aripiprazole, 1xbet 카지노 active ingredient in ABILIFY®, are valid, thus maintaining patent and regulatory protection for ABI® in 1xbet 카지노 United States until at least April 20, 2015.
1xbet 카지노 Pharmaceutical will keep striving to contribute to the welfare of patients suffering from mental illness through maximizing the therapeutic value of ABILIFY®.
Latest Pharmaceutical Bus1xbet 카지노ess related News Releases